Ongoing research continues to identify and validate new biomarkers for cancer. Advances in technologies like Next-Generation Sequencing (NGS) and liquid biopsy are expanding the range of detectable biomarkers and improving the accuracy of biochemical tests. These innovations hold promise for more precise and personalized cancer diagnostics and treatment.